Share on StockTwits

Edwards Lifesciences Corp (NYSE:EW) VP Carlyn D. Solomon sold 85,200 shares of the company’s stock on the open market in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $97.85, for a total value of $8,336,820.00. Following the completion of the sale, the vice president now directly owns 31,154 shares of the company’s stock, valued at approximately $3,048,419. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Edwards Lifesciences Corp (NYSE:EW) traded up 0.76% on Thursday, hitting $98.26. The stock had a trading volume of 619,598 shares. Edwards Lifesciences Corp has a 1-year low of $60.62 and a 1-year high of $99.35. The stock’s 50-day moving average is $91.97 and its 200-day moving average is $81.62. The company has a market cap of $10.419 billion and a price-to-earnings ratio of 14.07.

Edwards Lifesciences Corp (NYSE:EW) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.88 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.77 by $0.11. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $545.10 million. During the same quarter in the prior year, the company posted $0.82 earnings per share. The company’s quarterly revenue was up 11.2% on a year-over-year basis. On average, analysts predict that Edwards Lifesciences Corp will post $3.29 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on EW shares. Analysts at Zacks reiterated a “neutral” rating on shares of Edwards Lifesciences Corp in a research note on Wednesday. They now have a $104.00 price target on the stock. Separately, analysts at JMP Securities raised their price target on shares of Edwards Lifesciences Corp from $97.00 to $120.00 in a research note on Thursday, August 21st. They now have an “outperform” rating on the stock. Finally, analysts at Stifel Nicolaus raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday, July 31st. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Edwards Lifesciences Corp has an average rating of “Buy” and a consensus target price of $92.24.

Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.

Receive News & Ratings for Edwards Lifesciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.